SOLICITATION NOTICE
99 -- National Institute on Drug Abuse Notice of Intent
- Notice Date
- 3/16/2009
- Notice Type
- Modification/Amendment
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- National Institutes of HealthNational Institute on Drug AbuseBethesdaMD20892-7511
- ZIP Code
- 20892-7511
- Archive Date
- 4/14/2009
- Point of Contact
- Carol Lindsay,, Phone: 443-740-2451, Sheila R Zichos,, Phone: 443-740-2452
- E-Mail Address
-
clindsay@intra.nida.nih.gov, zichoss@intra.nida.nih.gov
- Small Business Set-Aside
- N/A
- Description
- This is a notice of intent, not a request for a proposal. A solicitation document will not be issued and proposals will not be requested. The National Institute on Drug Abuse (NIDA), Intramural Research Program (IRP) intends to solicit, negotiate and award a purchase order on a noncompetitive basis with Affymetrix, Inc., 3420 Central Expressway, Santa Clara, CA 95051. National Institutes on Drug Abuse (NIDA), Division of Intramural Research in Baltimore, Maryland requires 100K arrays, Mendel arrays, and assay kits which will be used for finding and studying genes related to drug abuse.Affymetrix is producing gene arrays that contain 1,000,000 SNPs (single nucleotide polymorphisms), the only arrays commercially available at that density. Analysis of SNP's in the human genome is crucial to our studies of drug abuse vulnerability loci. This gets close to reasonable power for detection of most of the addiction vulnerability loci in our samples, according to our modeling. The addition of this approach to our ongoing studies will put us in the forefront of drug abuse related genetic research. In accordance with FAR6.302-1, the supplies required by the agency are available from only one responsible source, Affymetrix, Inc. and no other supplier will satisfy the agency requirements. There are no licensed systems or instruments offered by third party providers that are able to use any components of the Affymetrix, Gene Chip System, including arrays. The highest SNP density commercially available is needed to identify drug abuse vulnerability loci and prove or disprove the idea of polygenic contributions of common allelic variants to drug abuse vulnerability. The acquisition is being conducted under simplified acquisition FAR 13 and is exempt from the requirements of FAR Part 6, Competition Requirement. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely with the discretion of the Government. Comments to this announcement, referencing synopsis number NIHDA2009085 may be submitted to the NIDA, IRP, 251 Bayview Boulevard, Suite 200, BRC Bldg., Rm 04A326, Baltimore, MD 21224, ATTN: Carol Lindsay
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=5dbab5fe49036f1fe04fcd620747bd3d&tab=core&_cview=1)
- Place of Performance
- Address: 251 Bayview Boulevard, Suite 200, BRC Building, RM 04A326, Baltimore, Maryland, 21224, United States
- Zip Code: 21224
- Zip Code: 21224
- Record
- SN01769970-W 20090318/090316215132-5dbab5fe49036f1fe04fcd620747bd3d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |